Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma. Issue 12 (December 2019)

• Record Type: Journal Article
• Authors: Soydal, Cigdem; Nak, Demet; Araz, Mine; Akkus, Pınar; Urun, Yuksel; Ozkan, Elgin; Kucuk, Nuriye Ozlem; Kir, Metin Kemal
• Is Part Of: Nuclear medicine communications. Volume 40:Issue 12(2019:Dec.)
• Publication Date: 2019-12
• Subjects: bone scintigraphy -- prostate carcinoma -- prostate-specific membrane antigen PET/computed tomography; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000001106
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : Aim: This study aims to assess the diagnostic performance of Ga-68 prostate-specific membrane antigen PET/computed tomography in the comparison of planar bone scintigraphy in the detection of bone metastases. Another purpose is to define the additional benefit of bone scintigraphy subsequent to prostate-specific membrane antigen PET/computed tomography and the role of prostate-specific membrane antigen PET/computed tomography in the treatment planning. Material and method: Forty-six patients with a median interval of 19 (range: 3–90) days between prostate-specific membrane antigen PET/computed tomography and bone scintigraphy included in the analysis. Diagnostic performance of both modalities was calculated and compared. Results: Prostate-specific membrane antigen PET/computed tomography and bone scintigraphy were performed for initial staging in 25 (54%), for evaluation of biochemical recurrence in 11 (24%) and metastatic castration-resistant prostate carcinoma in 10 (22%) patients. In the patient-based analysis sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for bone scintigraphy for detection of bone metastases were calculated as 50%, 19–29%, 32–39%, 32–39%, and 33–39%, respectively, based on whether equivocal findings were classified as positive or negative. For prostate-specific membrane antigen PET/computed tomography, these values were found significantly higher as 100%, 95–100%, 98–100%, 96–100%, and 100%, respectively. The diagnostic performance of bone scintigraphy and PET/computed tomography in clinical subgroups was analyzed, prostate-specific membrane antigen PET/computed tomography was superior to bone scintigraphy in three groups. Conclusion: In this retrospective study, prostate-specific membrane antigen PET/computed tomography was found to be superior to planar bone scintigraphy in the detection of bone metastases. Additional bone scintigraphy seems to be unnecessary in patients who underwent prostate-specific membrane antigen PET/computed tomography within three months period without additional treatment.